A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas

BACKGROUND: Cell-based  immunotherapy shows the therapeutic potential in sarcomas, in addition to angiogenesis-targeted tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI). Multi-antigen stimulated cell therapy-I (MASCT-I) technology is a sequential immune cell therapy for cancer,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yan, Li, Mei, Zhang, Bing, Yang, Cheng, Wang, Yaling, Zheng, Shuier, Tang, Lina, Zhou, Chenliang, Qian, Guowei, Huang, Yujing, Yu, Wenxi, Li, Hongtao, Wang, Yonggang, He, Aina, Shen, Zan, Zhang, Jianjun, Li, Xiaoshuang, Yang, Qingcheng, Hu, Haiyan, Yao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687909/
https://www.ncbi.nlm.nih.gov/pubmed/38031088
http://dx.doi.org/10.1186/s12916-023-03132-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687909/
https://www.ncbi.nlm.nih.gov/pubmed/38031088
http://dx.doi.org/10.1186/s12916-023-03132-x

Ejemplares similares